Peptide bioavailability—the fraction of administered peptide that reaches systemic circulation in active form—is a central challenge in peptide research. Understanding the factors that govern bioavailability enables researchers to select appropriate administration routes, design formulation strategies, and interpret pharmacological data with greater accuracy.
Barriers to Peptide Bioavailability
Enzymatic degradation: Peptides encounter proteases at every biological interface: pepsin and trypsin in the GI tract, DPP-IV and NEP in plasma, tissue-specific proteases at injection sites, and intracellular proteases after cellular uptake. The GI tract is particularly hostile—oral bioavailability of unmodified peptides is typically less than 1-2%. Even parenteral routes expose peptides to plasma and tissue proteases that limit bioavailability to 50-100% depending on susceptibility.
Membrane permeability: The size, polarity, and hydrogen bonding capacity of most peptides (>500 Da, >5 H-bond donors) violate Lipinski’s rules for passive membrane permeation. This limits absorption from the GI tract, distribution across the blood-brain barrier, and cellular uptake for intracellular targets. Only specialized structural features (cyclization, N-methylation, lipidation) enable meaningful passive permeability.
Hepatic first-pass metabolism: Peptides absorbed from the GI tract enter the portal circulation and pass through the liver before reaching systemic circulation. Hepatic peptidases can substantially degrade peptides during first-pass transit. Parenteral routes (SC, IM, IV) bypass first-pass metabolism entirely, which is a major reason for the predominance of injectable peptide formulations.
Route-Specific Bioavailability
Intravenous (IV): By definition, 100% bioavailability. IV injection is the reference standard for PK studies. Subcutaneous (SC): Typically 50-100% for peptides <10 kDa. Absorption via capillary diffusion and lymphatic drainage. Protease degradation at the injection site is the primary bioavailability-limiting factor. Intramuscular (IM): Generally 70-100% due to richer vascularization than SC tissue, providing faster absorption that reduces exposure to local proteases.
See our SC vs IM comparison guide for detailed route comparisons.
Strategies for Improving Bioavailability
Chemical modification: D-amino acid substitution, N-methylation, and unnatural amino acid incorporation reduce protease susceptibility. PEGylation reduces renal clearance and protease access. Cyclization improves both stability and permeability. Lipidation enables albumin binding for extended circulation.
Formulation approaches: Protease inhibitor co-administration (aprotinin, bestatin) can protect peptides from enzymatic degradation at the absorption site. Permeation enhancers (sodium caprate, SNAC) temporarily disrupt epithelial tight junctions to enable paracellular transport. Nanoparticle encapsulation (PLGA, chitosan, liposomes) provides sustained release and enzymatic protection.
Alternative routes: Intranasal administration delivers peptides to the CNS via olfactory and trigeminal nerve pathways, bypassing the BBB. Pulmonary delivery via inhalation provides large absorption surface area and reduced protease activity compared to the GI tract. Transdermal delivery using microneedle arrays physically penetrates the stratum corneum barrier.
Measuring Bioavailability
Absolute bioavailability (F) is calculated as: F = (AUC_route / AUC_IV) × (Dose_IV / Dose_route) × 100%. This requires parallel studies with IV and the test route at known doses in the same animal model. Blood sampling at multiple time points (typically 8-12 per animal) generates plasma concentration-time profiles for AUC calculation by the trapezoidal method. Peptide quantification in plasma uses LC-MS/MS methods with stable isotope-labeled internal standards for accuracy. For peptide identification in analytical samples, see our mass spectrometry guide.
Frequently Asked Questions
Why is oral bioavailability of peptides so low?
Three barriers combine to destroy oral peptides: gastric acid denatures tertiary structure, GI proteases (pepsin, trypsin, chymotrypsin) cleave peptide bonds, and the intestinal epithelium blocks absorption of intact peptide. Together, these barriers limit oral bioavailability to less than 1-2% for most unmodified peptides. The few orally available peptide drugs (cyclosporine, semaglutide) rely on extraordinary stability modifications and absorption enhancers.
How does peptide size affect bioavailability?
Smaller peptides (<1 kDa) generally show higher bioavailability due to faster absorption and lower protease susceptibility (fewer cleavage sites). Medium peptides (1-10 kDa) show variable bioavailability depending on sequence-specific protease vulnerability. Larger peptides and proteins (>10 kDa) shift from capillary to lymphatic absorption (slower but with reduced hepatic first-pass metabolism). The relationship is not strictly linear—sequence-specific factors often dominate over size effects.
What is the role of protein binding in peptide bioavailability?
Plasma protein binding (primarily to albumin) can both protect peptides from degradation (by shielding from proteases) and reduce free drug concentration at the receptor. Lipidated peptides like semaglutide (C18 fatty diacid chain) achieve extended half-life through reversible albumin binding, creating a bound reservoir that maintains free drug levels. The free fraction is the pharmacologically active form; total plasma concentration overestimates true exposure if binding is not accounted for.